Navigation Links
BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
Date:4/21/2009

NOVATO, Calif., April 21 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the initiation of a Phase 1/2 clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. The company expects to report initial results in the first half of 2010.

"We plan to leverage our clinical, manufacturing and regulatory expertise to bring a new therapeutic option to the significant number of untreated Morquio patients around the world," said Henry Fuchs, M.D., Chief Medical Officer of BioMarin. "GALNS has been shown in mice to reach important tissues including cartilage and different zones of the bone such as bone marrow, calcified bone and importantly, the growth plate. Our experiments have also shown that GALNS is taken up into human Morquio chondrocytes in vitro and reaches the lysosome to clear keratan sulfate."

Chris Hendriksz, M.D., Consultant in Metabolic Disorders, Birmingham Children's Hospital, added, "This is a very exciting announcement for our patients who have been waiting so long for a potential therapy. Hope of a therapeutic is now within reach for these patients, and Birmingham Children's Hospital is very honoured to be part of this exciting development."

The Phase 1/2 study is designed as an open-label, within-patient dose escalation trial in approximately 20 patients followed by a treatment continuation phase. All patients to be enrolled in the study have already been identified. During the dose escalation phase of the study, subjects will receive weekly intravenous infusions of BMN-110 in three consecutive 12-week dosing intervals. The objectives of the Phase 1/2 study will be to evaluate safety, pharmacokinetics, pharmacodynamics and
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
2. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
3. BioMarin Announces FDA Approval for Kuvan
4. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
5. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
6. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
7. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
10. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Los beneficios y ganancias ... nivel de gasto en investigación y desarrollo   ... 30 de septiembre de 2014) ZEISS aumentó sus ingresos ... euros (año anterior: 4.190 millones de euros) a pesar ... (EBIT) crecieron un 14 por ciento, a 360 millones ...
(Date:12/17/2014)...  Northstar Global Business Services, Inc. (OTCPink:MDIN) today ... made their final decision and has determined to ... effective December 15, 2014, and has resumed accepting ... book entry transfer services. All deposit restrictions have been ... fully "DTC Eligible", and has resumed electronic trading ...
(Date:12/17/2014)... 2014 , The ... hub of information concerning the biopharmaceutical Group,s national and international ... addition to the recently launched institutional website that is receiving ... enriched by a new chapter in the fascinating story of ... detailed and panoramic hub on the world of clinical research, ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... Company intends to release its second quarter 2011 financial results ... the U.S. financial markets.  The Company will also host a ... July 26, 2011 to discuss its financial results and provide ...
... BRUSSELS, June 30, 2011 UCB and Harvard University ... ceremony that took place in Boston last night in ... Belgium. (Photo: http://photos.prnewswire.com/prnh/20110630/NY28450 ) ... between industry and academia, with Harvard scientists continuing their ...
Cached Medicine Technology:Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings 2UCB Launches Research Alliance with Harvard University 2UCB Launches Research Alliance with Harvard University 3
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... with the healthcare sector have benefited the Massage ... Given the discretionary characteristics of industry products, the anticipated ... the five-year period has provided consumers with the means ... adults that have received a massage in a given ...
(Date:12/20/2014)... The print component of Healthy Aging is distributed within ... copies and an estimated readership of 420,000. The digital ... strategy and across a network of top news sites ... the campaign, click here . , The publication ... CTV’s The Social. Lainey Lui, Melissa Grelo, Traci ...
(Date:12/20/2014)... 2014 The Doctor’s Office Urgent Care of ... part of a decade. They’ve treated over 40,000 patients ... healthcare alternative to the Paramus area. , ... additions to their staff of top-notch board certified physicians: Christine ... These new doctors will work tirelessly to carry ...
(Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: Masashi ... focused portal on December 17th, 2014. , One ... US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 future ... Features, Choose from thousands of stock photos to decorate ...
(Date:12/20/2014)... December 20, 2014 Developers of ... of a new plugin for Final Cut Pro X ... “TranSlice Volume 5 allows users to create hand drawn ... Said Christina Austin, CEO of Pixel Film Studios. “TranSlice ... professionalism while maintaining an easy to use interface.” , ...
Breaking Medicine News(10 mins):Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... of Innovation in ... Provider, SILVER SPRING, Md. and CAMBRIDGE, Mass., ... for Medical Simulation (CMS) today,announced that they are ... facility,s already cutting edge simulation programs.,B-Line Medical will ...
... Inc.,(Nasdaq: CYNO ), a leading developer and ... systems, today announced that the company,will present at ... New York,City. Chief Financial Officer Timothy Baker ... financial results in a presentation,beginning at 1:30 p.m. ...
... DEL MAR, Calif., Sept. 10 "Portuguese speaking,Brazil ... surgery," claims Dr.,Barry L. Friedberg. In recognition of ... book, is now scheduled for,a Portuguese translation after ... University Press. Knowledge acquired in this book will,empower ...
... marketing campaign celebrates Freedom to Breathe Act, ... of a,new marketing campaign designed to educate and ... statewide smoke-free law that goes into effect,on October ... workplaces smoke-free,including bars, restaurants and private clubs. Called ...
... healthy women, breast cancer survivors reported more days of ... in the October 15, 2007 issue of CANCER, a ... who received both chemotherapy and radiotherapy reported the most ... complaint in the general population and, anecdotally, common among ...
... be deadly for skiers, mountain climbers, regardless of fitness , ... high altitude pulmonary edema (HAPE) -- a life-threatening buildup of ... -- has been launched at the University of Edinburgh in ... at altitudes as low as 2,500 meters and can affect ...
Cached Medicine News:Health News:B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership 2Health News:B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership 3Health News:Cynosure to Present at the Maxim Group Growth Conference 2Health News:Cosmetic Surgery & Exotic Brazil 2Health News:Fresh Air Campaign to Showcase Minnesotans' Love of Smoke-Free Air 2Health News:Chemotherapy may be culprit for fatigue in breast cancer survivors 2
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
STABIBAG Hydrophilic Acrylic Lens....
BIGBAG Hydrophilic Acrylic Lens for high myopia....
One piece multifocal acrylic intraocular lens....
Medicine Products: